AsiaPharm Of China, GlycoMar Of Scotland In R&D Tie
This article was originally published in PharmAsia News
Executive Summary
China's AsiaPharm and GlycoMar, a biotech based in Scotland, have signed an agreement to conduct research and development for drugs based on marine glycomolecules. The agreement was reached as AsiaPharm, based in Shanghai, faces a takeover bid by MBK Partners, a Korean private-equity firm. Under the agreement with GlycoMar, the Scottish firm is to supply purified marine glycans to AsiaPharm to be studied for possible drug applications. The companies would collaborate on any candidates that result. (Click here for more